Preclinical vs Phase 1 — Metabolic Deal Valuation Comparison

Preclinical Median Upfront

$122M

Total: $1.6B

Phase 1 Median Upfront

$365M

Total: $2.9B

Stage Premium

83%

Phase 1 premium over Preclinical

Preclinical Royalties

6.7%-13.4%

vs Phase 1: 10.7%-20.1%

Model Your Deal

Market Analysis

The Preclinical to Phase 1 transition in metabolic represents a significant value inflection point. Phase 1 deals carry a median total deal value of $2.9B compared to $1.6B at Preclinical, a 83% premium reflecting clinical de-risking. Upfront payments increase from $122M to $365M.

Deal structures shift as assets advance. Preclinical deals allocate 8% to upfront and 92% to milestones, while Phase 1 deals shift to 12%/88%. Development milestones move from $590M to $770M, and royalty rates evolve from 6.7%-13.4% to 10.7%-20.1%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Preclinical to Phase 1 in metabolic?

Phase 1 metabolic deals command a 83% premium over Preclinical in total deal value ($2.9B vs $1.6B). Upfronts increase from $122M to $365M, reflecting the de-risking value of clinical progression.

How do deal structures differ between Preclinical and Phase 1 in metabolic?

Preclinical deals are more milestone-weighted (92% milestones), reflecting higher clinical risk. Phase 1 deals shift toward higher upfront allocations (12% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a metabolic asset?

The optimal licensing window depends on strategic priorities. Preclinical assets offer lower entry cost for licensees, while Phase 1 assets provide more certainty. The 83% premium from Preclinical to Phase 1 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included